Search research articles
Contact Us
Filters
Showing results (141-150 of 277) with videos related to
Page
of 28
Sort By:
Journal of Hematology & Oncology
|
May 30, 2015
HER2/neu-directed therapy for biliary tract cancer
Milind Javle, Chaitanya Churi, HyunSeon C Kang, et al.
Cancers
|
March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Filip Janku, Grace M Choong, Mateusz Opyrchal, et al.
British Journal of Cancer
|
March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
Shuyang Yao, Filip Janku, Vivek Subbiah, et al.
Scientific Reports
|
March 13, 2021
Associations between the gut microbiome and fatigue in cancer patients
Joud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Blood Advances
|
March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease
Eli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Page
of 28
Search research articles
Search
Showing results (141-150 of 277) with videos related to
Sort By:
Page
of 28
Journal of Hematology & Oncology
|
May 30, 2015
HER2/neu-directed therapy for biliary tract cancer
Milind Javle, Chaitanya Churi, HyunSeon C Kang, et al.
Cancers
|
March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Filip Janku, Grace M Choong, Mateusz Opyrchal, et al.
British Journal of Cancer
|
March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
Shuyang Yao, Filip Janku, Vivek Subbiah, et al.
Scientific Reports
|
March 13, 2021
Associations between the gut microbiome and fatigue in cancer patients
Joud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Blood Advances
|
March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease
Eli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Page
of 28